Skip to main content
Caplight Logo









Pharmability AB

Pharmability AB

Private
StockholmHealthcare & Life Scienceshttps://pharmability.com/

Last Round

Early Funding

Apr 9, 2025

Total Funding Raised

$5.66M

Company Overview

Pharmability AB is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis.

Sector

Healthcare & Life Sciences

Verticals

Compliance & Risk, Quality Management, Biotechnology, Clinical Trials, RegTech

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regulatory affairspharmacovigilancequality assuranceGxP compliancepharma consultingsafety monitoringmarket authorizationregulatory complianceinterim managementpharma regulatorylife sciences consultingdrug development supportpost-market surveillanceregulatory servicescompliance outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pharmability AB Comparables

Compare Pharmability AB with similar companies based on industry and business-model similarity.

Pharmability AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Abrahamsson Pharma Consulting AB
89%
Scandinavian Regulatory Services AB
88%
RegSmart Life Science AB
87%

Pharmability AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 9, 2025
GrantAug 1, 2024
Early FundingNov 20, 2020

Key People

Founding team and executive leadership

Leo Holmgren

CEO, Strategic Advisor, Board Member

Executive Team

Pharmability AB Investors

Notable investors and investment history

Pharmability AB investors
InvestorRounds
Almi Invest ABEarly Funding
VinnovaGrant
ScietyEarly Funding
SwelifeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    Partnered with Bachem Americas, Inc. for atopic dermatitis therapy.

  • Nov 6, 2025

    Strengthening collaboration with Zelmic AB.

Pharmability AB Filings

Explore SEC and related filing metadata, where available.

Pharmability AB filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pharmability AB's valuation, stock price, and market status.

Is Pharmability AB a public or private company?

Pharmability AB is a private company.

What is the current stock price of Pharmability AB?

Pharmability AB is a private company, so its shares have no public market price. Caplight tracks Pharmability AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Pharmability AB worth (valuation)?

Valuation information for Pharmability AB is not publicly available.

Can I buy Pharmability AB stock?

Pharmability AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Pharmability AB's last funding round?

Pharmability AB's most recent funding round was Early Funding on April 9, 2025.

Who are the main investors in Pharmability AB?

Key investors in Pharmability AB include Sciety.

Will Pharmability AB IPO soon?

No public IPO plans have been announced for Pharmability AB.

How can I track Pharmability AB secondary market activity?

Caplight tracks bids, offers, and trades in Pharmability AB's shares on secondary markets.

Firmographic Details

HeadquartersStockholm
Employee Range3
Year Founded2018
Last FundingApr 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?